- Home
- FURY vs CRDL Comparison
FURY vs CRDL Comparison
Compare FURY & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- CRDL
- Stock Information
- Founded
- FURY 2008
- CRDL 2017
- Country
- FURY Canada
- CRDL Canada
- Employees
- FURY N/A
- CRDL N/A
- Industry
- FURY Precious Metals
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FURY Basic Materials
- CRDL Health Care
- Exchange
- FURY Nasdaq
- CRDL Nasdaq
- Market Cap
- FURY 84.1M
- CRDL 90.4M
- IPO Year
- FURY N/A
- CRDL N/A
- Fundamental
- Price
- FURY $0.72
- CRDL $1.04
- Analyst Decision
- FURY Strong Buy
- CRDL Strong Buy
- Analyst Count
- FURY 2
- CRDL 2
- Target Price
- FURY $1.40
- CRDL $9.00
- AVG Volume (30 Days)
- FURY 1.2M
- CRDL 736.0K
- Earning Date
- FURY 11-11-2025
- CRDL 11-13-2025
- Dividend Yield
- FURY N/A
- CRDL N/A
- EPS Growth
- FURY N/A
- CRDL N/A
- EPS
- FURY N/A
- CRDL N/A
- Revenue
- FURY N/A
- CRDL N/A
- Revenue This Year
- FURY N/A
- CRDL N/A
- Revenue Next Year
- FURY N/A
- CRDL N/A
- P/E Ratio
- FURY N/A
- CRDL N/A
- Revenue Growth
- FURY N/A
- CRDL N/A
- 52 Week Low
- FURY $0.35
- CRDL $0.77
- 52 Week High
- FURY $0.89
- CRDL $2.24
- Technical
- Relative Strength Index (RSI)
- FURY 53.60
- CRDL 44.74
- Support Level
- FURY $0.70
- CRDL $1.01
- Resistance Level
- FURY $0.88
- CRDL $1.09
- Average True Range (ATR)
- FURY 0.07
- CRDL 0.04
- MACD
- FURY 0.00
- CRDL -0.00
- Stochastic Oscillator
- FURY 42.54
- CRDL 44.21
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.